In a study by Ichimura et al., cancer was diagnosed in 37.5% of patients with anti-NXP-2 antibodies, yet the reliability of this observation is limited by the rarity of this serological profile in the study group (only eight patients with anti-NXP-2) [72]. This evidence concerns the gene MORC3 and cancer.